Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting

CONCLUSIONS: During the maintenance of VDZ therapy, the majority of VDZ TCs were within the suggested range. Measurement of VDZ TC did not lead to any treatment changes in two-thirds of patients. Dose optimization occurred in a quarter of patients and a third of them benefited from it.PMID:34154506 | DOI:10.1080/00365521.2021.1938206

Source: Scandinavian Journal of Gastroenterology - June 22, 2021 Category: Gastroenterology Authors: Sara Kolehmainen Tero Ylisaukko-Oja Jari Jokelainen Mirkka Koivusalo T Sakari Jokiranta Taina Sipponen Source Type: research